Article
Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
Clinical and vaccine immunology : CVI - 1 Aug 2008
Lapa Joyce A, Sincock Stephanie A, Ananthakrishnan Madhumita, Porter Chad K, Cassels Frederick J, Brinkley Carl, Hall Eric R, van Hamont John, Gramling Joseph D, Carpenter Colleen M, Baqar S, Tribble David R
Abstract excerpt
An oral, microencapsulated anti-colonization factor 6 antigen (meCS6) vaccine, with or without heat-labile enterotoxin with mutation R192G (LT(R192G)) (mucosal adjuvant), against enterotoxigenic Escherichia coli (ETEC) was evaluated for regimen and adjuvant effects on safety and immunogenicity. Sixty subjects were enrolled into a three-dose, 2-week interval or four-dose, 2-day interval regimen. Each regimen was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.